Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
– Topline results anticipated in first half of 2020 – DALLAS–(BUSINESS WIRE)–Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class…